Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.

Neurosense Therapeutics Ltd (NRSN)

Neurosense Therapeutics Ltd (NRSN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
World-Renowned Alzheimer's Expert Prof. Steven Arnold Joins NeuroSense SAB PR Newswire - Thu Jan 8, 7:45AM CST

Alzheimer's Clinical and Biomarker Outcomes Expected in Q1 2026

NRSNW : 0.3100 (-3.03%)
NRSN : 0.9500 (-4.09%)
NeuroSense Confirms Favorable Safety and Tolerability of PrimeC in an Alzheimer's Phase 2 Study PR Newswire - Mon Dec 22, 2025

Clinical and Biomarker Outcomes Expected to Be Reported in Q1 2026

NRSN : 0.9500 (-4.09%)
NeuroSense to Hold Pre-NDS Meeting with Health Canada in April 2026 PR Newswire - Thu Dec 4, 2025

CAMBRIDGE, Mass. , Dec. 4, 2025 /PRNewswire/ --  NeuroSense Therapeutics Ltd.  (NASDAQ: NRSN) ("NeuroSense"), a late-clinical stage biotechnology company developing novel treatments for severe...

NRSNW : 0.3100 (-3.03%)
NRSN : 0.9500 (-4.09%)
NeuroSense Receives FDA Clearance to Initiate Pivotal Phase 3 Trial for PrimeC in ALS PR Newswire - Mon Nov 24, 2025

CAMBRIDGE, Mass. , Nov. 24, 2025 /PRNewswire/ -- NeuroSense Therapeutics Ltd.  (Nasdaq: NRSN) ("NeuroSense"), a late-clinical stage biotechnology company developing novel treatments for severe...

NRSN : 0.9500 (-4.09%)
NeuroSense to Host Investor Webinar on December 8, 2025 PR Newswire - Mon Nov 3, 2025

Business, regulatory and clinical updates will be provided

NRSNW : 0.3100 (-3.03%)
NRSN : 0.9500 (-4.09%)
Neurosense Therapeutics Ltd. (NRSN) Receives a New Rating from Noble Financial Tipranks - Fri Oct 17, 2025

Neurosense Therapeutics Ltd. received a Buy rating and a $9.00 price target from Noble Financial analyst Robert LeBoyer on October 14. The company’s shares closed yesterday at $1.24.Elevate Your Investing...

NRSN : 0.9500 (-4.09%)
NeuroSense Announces Promising Alzheimer’s Biomarker Reductions with PrimeC Tipranks - Tue Oct 7, 2025

Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Neurosense...

NRSN : 0.9500 (-4.09%)
NeuroSense: PrimeC Produces Statistically Significant Reductions in Alzheimer's Disease Biomarkers PR Newswire - Mon Oct 6, 2025

CAMBRIDGE, Mass. , Oct. 6, 2025 /PRNewswire/ -- NeuroSense Therapeutics Ltd.  (NASDAQ: NRSN) ("NeuroSense"), a late-clinical stage biotechnology company developing novel treatments for severe...

NRSN : 0.9500 (-4.09%)
NeuroSense's Drug Candidate Shows Early Signals of Benefit in Alzheimer's Patient-Derived Neurons PR Newswire - Wed Sep 10, 2025

Initial Phase 2 RoAD trial results demonstrate improvements in brain-cell connectivity and health, with a favorable safety profile

NRSN : 0.9500 (-4.09%)
NeuroSense Therapeutics Announces $500,000 Private Placement at Premium to Market Price PR Newswire - Thu Sep 4, 2025

Financing at 40% premium to market price provides near-term bridge to anticipated milestones

NRSN : 0.9500 (-4.09%)

Barchart Exclusives

Trump Just Took Aim at Health Insurance ‘Middlemen.’ What Does That Mean for UnitedHealth Stock? Barchart - 33 minutes ago
UnitedHealth stock sinks as President Trump says he will get rid of insurance brokers and corporate middlemen. Bernstein still recommends buying UNH shares at current levels. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot